Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Redx raises $36M in Series A funding to support Phase 2 trial of RXC008 for Crohn's disease, led by Abingworth.

PRIVATEAug 27, 2026•about 4 hours ago

Amount Raised

$36 Million

Round Type

Series A

BiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Investors

5 Am VenturesNext Bio CapitalRedmileBritish Business BankAbingworth

Description

Redx secured $36 million in Series A funding to advance its drug candidate RXC008 through Phase 2 trials for Crohn's disease. This financing will help demonstrate the drug's effectiveness in tackling fibrosis. The round was led by Abingworth, with contributions from other investors including British Business Bank. Redx plans to utilize this funding for operations beyond its pending merger with Skye Bioscience.

Company Information

Company

Redx

About

Redx is a biopharmaceutical company focused on discovering and developing innovative medicines for cancer and fibrosis. The company is developing RXC008, a gut-restricted drug candidate aimed at treating Crohn's disease by targeting fibrosis rather than inflammation. Their approach addresses the unmet need for therapies that prevent disease progression in fibrostenotic Crohn’s patients. Redx is transitioning to operate as Fibrx Therapeutics after a merger.

Don't miss Redx's next move

Get an email the moment Redx raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Redx's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Redx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.